Prognosis of the Primary Pulmonary Hypertension from the Hemodvnamic Point of View Nariaki Kanemoto 1 , Johji Hosokawa 2 1Department of Internal Medicine. Nekkan Hospital 2Department of Cardiology, Shohnann Kamakura Hospital Keyword: 血管拡張薬療法 , 原発性肺高血圧症 , 自然歴 , 肺循環動態 , vasodilator therapy , primary pulmonary hypertension , natural history , pulmonary hemodynamics pp.485-489
Published Date 1997/5/15
DOI https://doi.org/10.11477/mf.1404901479
  • Abstract
  • Look Inside

Vasodilator therapy was introduced for the treatment of primary pulmonary hypertension (PPH) some 10 years ago. However, inclusion criteria have not yet been determined. This study attempted to clarify the natural history of PPH in terms of pulmonary hemodynamics and to evaluate vasodilator therapy. Subjects were 51 patients with PPH. We divided the patients into 4 groups by cardiac index (CI)=2.4 l/min/m2 and systolic pulmonary artery pressure (PA)=90 mmHg. Subset I consisted of patients with CI>2.4 //min/m2 and PA <90 mmHg with the other subsets (II~IV) following coun-terclockwise. Every patient in subset I survived 2 years or more. Survival rates greater than 2 years in subsets II to IV were 79, 40, and 25%, respectively. The survival rate determined by the Kaplan-Meier method, from the day after cardiac catheterization showed statistically significant differences between each subset. We conclude that the prognosis of PPH can be determined using our classification. This can also be used to monitor the efficacy of vasodilator therapy.

Copyright © 1997, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1200 印刷版ISSN 0452-3458 医学書院